Literature DB >> 10603621

Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

R Hohlfeld1.   

Abstract

This review first addresses several general aspects of the immunotherapy of multiple sclerosis. Next, two approved immunomodulatory treatments, interferon-beta and copolymer-1 (glatiramer acetate), are reviewed in more detail. Finally, other immunosuppressive therapies and experimental strategies are briefly discussed.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10603621      PMCID： PMC1692674          DOI： 10.1098/rstb.1999.0513

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN： 0962-8436            Impact factor:   6.237


  71 in total

1.  Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development.

Authors:  B L McRae; R T Semnani; M P Hayes; G A van Seventer
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

2.  Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b.

Authors:  S Chabot; G Williams; V W Yong
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

Review 3.  Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.

Authors:  R Hohlfeld
Journal:  Brain       Date:  1997-05       Impact factor: 13.501

Review 4.  A brief history of the use of interferons as treatment of multiple sclerosis.

Authors:  L Jacobs; K P Johnson
Journal:  Arch Neurol       Date:  1994-12

5.  Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

Authors:  K M Myhr; T Riise; F E Green Lilleås; T G Beiske; E G Celius; A Edland; D Jensen; J P Larsen; R Nilsen; M W Nortvedt; A I Smievoll; C Vedeler; H I Nyland
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

6.  Interferon-beta is a potent promoter of nerve growth factor production by astrocytes.

Authors:  T Boutros; E Croze; V W Yong
Journal:  J Neurochem       Date:  1997-09       Impact factor: 5.372

7.  Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.

Authors:  H T Lu; J L Riley; G T Babcock; M Huston; G R Stark; J M Boss; R M Ransohoff
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

Review 8.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

9.  Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction.

Authors:  E M Martínez-Cáceres; J Río; M Barrau; I Durán; C Borrás; M Tintoré; X Montalban
Journal:  Ann Neurol       Date:  1998-10       Impact factor: 10.422

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422
View more
  2 in total

1.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Dene Simpson; Stuart Noble; Caroline Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.